Nephro-oncology: a link in evolution

References

• Lameire NH, Flombaum CD, Moreau D, Ronco C. Acute renal failure in cancer patients. Ann Med. 2005;37(1):13–25
   PubMed Web of Science ®Google Scholar
• Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823–2831
   PubMed Web of Science ®Google Scholar
• Wong G, Hayen A, Chapman JR, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009;20(6):1341–1350
   PubMed Web of Science ®Google Scholar
• Arican A, Ozdemir N, Sezer S, et al. Tumor markers in hemodialysis patients. Transplant Proc. 1999;31(8):3367–3368
   PubMed Web of Science ®Google Scholar
• Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet. 1999;354(9173):93–99
   PubMed Web of Science ®Google Scholar
• Darmon M, Ciroldi M, Thiery G, Schlemmer B, Azoulay E. Clinical review: Specific aspects of acute renal failure in cancer patients. Crit Care. 2006;10(2):211. doi: 10.1186/cc4907
   PubMed Web of Science ®Google Scholar
• Ogawa T, Niho S, Nagai S, et al. Moderate renal dysfunction may not require a cisplatin dose reduction: A retrospective study of cancer patients with renal impairment. Int J Clin Oncol. 2013;18(6):977–982
   PubMed Web of Science ®Google Scholar
• Pabla N, Dong Z. Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007
   PubMed Web of Science ®Google Scholar
• Sahni V, Choudhury D, Ahmed Z. Chemotherapy-associated renal dysfunction. Nat Rev Nephrol. 2009;5(8):450–462
   PubMed Web of Science ®Google Scholar
• Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: Clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28(25):3979–3986
   PubMed Web of Science ®Google Scholar
• Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713–1721
   PubMed Web of Science ®Google Scholar
• McCullough PA, Sandberg KR. Epidemiology of contrast-induced nephropathy. Rev Cardiovasc Med. 2003;4(Suppl 5):S3–S9
   Google Scholar
• Section 4: Contrast-induced AKI. Kidney Int Suppl. 2012;2(1):69–88
   Google Scholar
• Lacquaniti A, Buemi F, Lupica R, et al. Can neutrophil gelatinase-associated lipocalin help depict early contrast material-induced nephropathy? Radiology. 2013;267(1):86–93
   PubMed Web of Science ®Google Scholar
• Raftopoulos H. Diagnosis and management of hyponatremia in cancer patients. Support Care Cancer. 2007;15(12):1341–1347
   PubMed Web of Science ®Google Scholar
• Vantyghem MC, Balavoine AS, Wemeau JL, Douillard C. Hyponatremia and antidiuresis syndrome. Ann Endocrinol. 2011;72(6):500–512
   PubMed Web of Science ®Google Scholar
• Bolignano D, Coppolino G, Criseo M, Campo S, Romeo A, Buemi M. Aquaretic agents: What’s beyond the treatment of hyponatremia? Curr Pharm Des. 2007;13(8):865–871
   PubMed Web of Science ®Google Scholar
• North WG. Gene regulation of vasopressin and vasopressin receptors in cancer. Exp Physiol. 2000;85(Spec No):27S–40S
   PubMed Web of Science ®Google Scholar
• Bolignano D, Medici MA, Coppolino G, et al. Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R). Urol Oncol. 2010;28(6):642–647
   PubMed Web of Science ®Google Scholar
• Salahudeen AK, Doshi SM, Shah P. The frequency, cost, and clinical outcomes of hypernatremia in patients hospitalized to a comprehensive cancer center. Support Care Cancer. 2013;21(7):1871–1878
   PubMed Web of Science ®Google Scholar
• Bergman PJ. Paraneoplastic hypercalcemia. Top Companion Anim Med. 2012;27(4):156–158
   PubMed Web of Science ®Google Scholar
• Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diab Obes. 2011;18(6):339–346
   PubMed Web of Science ®Google Scholar
• Janovska Z. Bisphosphonate-related osteonecrosis of the jaws. A severe side effect of bisphosphonate therapy. Acta Med. 2012;55(3):111–115
   Google Scholar
• Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281–289
   PubMed Web of Science ®Google Scholar
• Iguchi K, Tatsuda Y, Usui S, Hirano K. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Eur J Pharmacol. 2010;641(1):35–40
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377(9768):813–822
   PubMed Web of Science ®Google Scholar
• Ikesue H, Tsuji T, Hata K, et al. Time course of calcium concentrations and risk factors for hypocalcemia in patients receiving denosumab for the treatment of bone metastases from cancer. Ann Pharmacother. 2014;48(9):1159–1165
   PubMed Web of Science ®Google Scholar
• Szentirmai M, Constantinou C, Rainey JM, Loewenstein JE. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer. West J Med. 1995;163(6):577–578
   PubMedGoogle Scholar
• Cooper MS, Gittoes NJ. Diagnosis and management of hypocalcaemia. BMJ. 2008;336(7656):1298–1302
   PubMed Web of Science ®Google Scholar
• Barni S. Rosti G. Pronzato P. L'anemia nel paziente oncologico. In: Kluwer Health Italia, ed. L’Anemia in oncologia. Milano, MI: Springer; 2009:1–181
   Google Scholar
• Buemi M, Fazio MR, Bolignano D, et al. Renal complications in oncohematologic patients. J Investig Med. 2009;57(8):892–901
   PubMed Web of Science ®Google Scholar
• Bennett CL, Spiegel DM, Macdougall IC, et al. A review of safety, efficacy, and utilization of erithropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: A report from the southern network on adverse reactions (SONAR). Semin Thromb Hemost. 2012;38(8):783–796
   PubMed Web of Science ®Google Scholar
• Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–1854
   PubMed Web of Science ®Google Scholar
• Raghavendran M, Rastogi A, Dubey D, et al. Stones associated renal pelvic malignancies. Indian J Cancer. 2003;40(3):108–112
   PubMedGoogle Scholar
• Shebl FM, Warren JL, Eggers PW, Engels EA. Cancer risk among elderly persons with end-stage renal disease: A population-based case-control study. BMC Nephrol. 2012;13:65
   PubMed Web of Science ®Google Scholar
• Port FK, Ragheb NE, Schwartz AG, Hawthorne VM. Neoplasms in dialysis patients: A population-based study. Am J Kidney Dis. 1989;14:119–123
   PubMed Web of Science ®Google Scholar
• Kamata T, Fushimi K. Prevalence of prostate cancer in end-stage renal disease patients. Urol Int. 2008;80:419–424
   PubMed Web of Science ®Google Scholar
• Marquardt P, Krause R, Schaller M, Bach D, Von Gersdorff G. Vitamin D and cancer in incident hemodialysis patients. Anticancer Res. 2015;35:1181–1188
   PubMedGoogle Scholar
• Coppolino G, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumour markers and kidney function: A systematic review. BioMed Res Int. 2014;2014:647541
   Web of Science ®Google Scholar
• Tong HL, Dong ZN, Wen XY, Gao J, Wang B, Tian YP. Impact of chronic kidney disease on serum tumor markers concentrations. Chin Med J (Engl). 2013;126(2):274–279
   PubMed Web of Science ®Google Scholar
• Bruun L, Savage C, Cronin AM, Hugosson J, Lilja H, Christensson A. Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant. 2009;24(4):1238–1241
   PubMed Web of Science ®Google Scholar
• Hsiao RJ, Mezger MS, O’Connor DT. Chromogranin A in uremia: Progressive retention of immunoreactive fragments. Kidney Int. 1990;37(3):955–964
   PubMed Web of Science ®Google Scholar
• Drüeke TB, Massy ZA. Beta2-microglobulin. Semin Dial. 2009;22(4):378–380
   PubMed Web of Science ®Google Scholar
• Xiaofang Y1, Yue Z, Xialian X, Zhibin Y. Serum tumour markers in patients with chronic kidney disease. Scand J Clin Lab Invest. 2007;67(6):661–667
   PubMed Web of Science ®Google Scholar
• Filella X, Cases A, Molina R, et al. Tumor markers in patients with chronic renal failure. Int J Biol Mark. 1990;5(2):85–88
   PubMedGoogle Scholar
• Zeferos N, Digenis GE, Christophoraki M, Alexopoulos I, Kostakis Gyftaki AH, Moulopoulos S. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron. 1991;59(4):618–620
   PubMed Web of Science ®Google Scholar
• Menzin AW, Kobrin S, Pollak E, Goodman DBP, Rubin SC. The effect of renal function on serum levels of CA 125. Gynecol Oncol. 1995;58(3):375–377
   PubMed Web of Science ®Google Scholar
• Lye WC, Tambyah P, Leong SO, Lee EJ. Serum tumor markers in patients on dialysis and kidney transplantation. Adv Perit Dial. 1994;10:109–111
   PubMedGoogle Scholar
• Arik N, Adam B, Akpolat T, Hasil K, Tabak S. Serum tumour markers in renal failure. Int Urol Nephrol. 1996;28(4):601–604
   PubMedGoogle Scholar
• Maoujoud O1, El Machtani S, Asseraji M, et al. Serum tumor markers in hemodialysis patients. Int J Artif Organs. 2014;37(2):126–132
   PubMed Web of Science ®Google Scholar
• García-Sánchez C1, Corchuelo-Maillo C, Congregado-Ruiz CB, et al. PSA levels in patients on hemodialysis treatment. Arch Esp Urol. 2013;66(10):939–944
   PubMed Web of Science ®Google Scholar
• Tzitzikos G, Saridi M, Filippopoulou T, et al. Measurement of tumor markers in chronic hemodialysis patients. Saudi J Kidney Dis Transplant. 2010;21(1):50–53
   PubMedGoogle Scholar
• Estakhri R, Ghahramanzade A, Vahedi A, Nourazarian A. Serum levels of CA15-3, AFP, CA19-9 and CEA tumor markers in cancer care and treatment of patients with impaired renal function on hemodialysis. Asian Pac J Cancer Prev. 2013;14(3):1597–1599
   PubMedGoogle Scholar
• Bertolini L, Meschi M, Detrenis S, Maggiore U, Savazzi G. Serum concentration of some tumor markers in renal failure. Recenti Prog Med. 2005;96(5):221–225
   PubMedGoogle Scholar
• Ronco C. Biomarkers for acute kidney injury: Is NGAL ready for clinical use? Crit Care. 2014;18(6):680. doi: 10.1186/s13054-014-0680-0
   PubMed Web of Science ®Google Scholar
• Bolignano D, Coppolino G, Lacquaniti A, Nicocia G, Buemi M. Pathological and prognostic value of urinary neutrophil gelatinase-associated lipocalin in macroproteinuric patients with worsening renal function. Kidney Blood Press Res. 2008;31(4):274–279
   PubMed Web of Science ®Google Scholar
• Perrin C, Patard JJ, Jouan F, et al. The neutrophil gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma. Clin Neuropathol. 2010;29(5):317–322
   PubMed Web of Science ®Google Scholar
• Bratt T. Lipocalins and cancer. Biochim Biophys Acta. 2000;1482(1–2):318–326
   PubMed Web of Science ®Google Scholar
• Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maass N, Friedl A. Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 2008;108(3):389–397
   PubMed Web of Science ®Google Scholar
• Fernàndez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metallo-proteinase-9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11(15):5390–5395
   PubMed Web of Science ®Google Scholar